The corporate team at Penningtons Manches has advised Guildford-based MedPharm Limited on a growth equity investment from private equity firm Ampersand Capital Partners.
MedPharm, founded 20 years ago, has established itself as a trusted developer of topical and transdermal products for the pharmaceutical drug development community. The company’s services include formulation development, performance testing and clinical trials manufacturing at its facilities in Guildford, UK and Durham, North Carolina in the US. The investment from Ampersand will enable MedPharm to expand its service offering in topical and transdermal pharmaceutical development and manufacturing and increase international contract development and manufacturing organisation (CDMO) market coverage.
Founded in the late 1980s and based in Boston, Ampersand focuses exclusively on growth equity investments in lower middle market healthcare companies, working with founder-owned businesses to help take companies to the next level.
Corporate partner Rob Hayes led the Penningtons Manches team, which included specialist lawyers from the firm’s intellectual property, real estate, corporate tax, employment and pensions teams.
Rob commented: “I have worked with Andy and Marc at MedPharm for the past seven years and it’s fantastic to see their hard work pay dividends with this investment from Ampersand. There was a strong synergy between the company and the investor throughout the process, which I’ve no doubt will form a solid foundation for the business going forward.”
Dr Andrew Muddle, CEO of MedPharm, said: “Rob’s team did a great job in helping us get the deal over the line. They were responsive, commercial, pragmatic and very easy to deal with. The advice was always clear and concise which was very welcome on a transaction with so many moving parts.”
For detailed insight into US-UK inward investment trends read our recently published report.